Hyperfine (HYPR) Cash from Investing Activities (2021 - 2026)
Hyperfine (HYPR) posted Cash from Investing Activities of -$242000.0 for Q1 2026, down 284.13% on a QoQ basis from -$63000.0 in Q4 2025, and up 48.73% year-over-year from -$162712.3 in Q1 2025.
Hyperfine (HYPR) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Hyperfine's Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$242000.0 for Q1 2026.
- Quarterly Cash from Investing Activities rose 48.73% year-over-year to -$242000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$955000.0 (down 34.51% YoY) and the FY2025 annual result came in at -$1.2 million, down 209.4% from the prior year.
- Cash from Investing Activities was -$242000.0 for Q1 2026 at Hyperfine, down from -$63000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $54000.0 in Q2 2022 and bottomed at -$520000.0 in Q2 2025.
- A 5-year average of -$188176.5 and a median of -$159000.0 in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 110.69% — and 2025, when it slumped 687.5%.
- Hyperfine's Cash from Investing Activities stood at -$158000.0 in 2022, then tumbled by 63.29% to -$258000.0 in 2023, then jumped by 96.9% to -$8000.0 in 2024, then slumped by 687.5% to -$63000.0 in 2025, then plunged by 284.13% to -$242000.0 in 2026.
- Business Quant data shows HYPR's Cash from Investing Activities at -$242000.0 in Q1 2026, -$63000.0 in Q4 2025, and -$130000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Hyperfine | 94.51 Mn | 53.23 Mn | 1.98 Mn | -242,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -242,000.00 |
| Mar 31, 2026 | -242,000.00 |
| Dec 31, 2025 | -63,000.00 |
| Dec 31, 2025 | -63,000.00 |
| Sep 30, 2025 | -130,000.00 |
| Sep 30, 2025 | -130,000.00 |
| Jun 30, 2025 | -520,000.00 |
| Jun 30, 2025 | -520,000.00 |
| Mar 31, 2025 | -472,000.00 |
| Mar 31, 2025 | -472,000.00 |
| Dec 31, 2024 | -8,000.00 |
| Dec 31, 2024 | -8,000.00 |
| Sep 30, 2024 | -159,000.00 |
| Sep 30, 2024 | -159,000.00 |
| Jun 30, 2024 | -71,000.00 |
| Jun 30, 2024 | -71,000.00 |
| Mar 31, 2024 | -145,000.00 |
| Mar 31, 2024 | -145,000.00 |
| Dec 31, 2023 | -258,000.00 |
| Dec 31, 2023 | -258,000.00 |